Nico van Walree

465 total citations
10 papers, 326 citations indexed

About

Nico van Walree is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Nico van Walree has authored 10 papers receiving a total of 326 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 7 papers in Oncology and 2 papers in Surgery. Recurrent topics in Nico van Walree's work include Lung Cancer Treatments and Mutations (6 papers), Cancer survivorship and care (3 papers) and Lung Cancer Research Studies (3 papers). Nico van Walree is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Cancer survivorship and care (3 papers) and Lung Cancer Research Studies (3 papers). Nico van Walree collaborates with scholars based in Netherlands, Belgium and Finland. Nico van Walree's co-authors include Huub Belderbos, Nico van Zandwijk, Harry Bartelink, Giuseppe Giaccone, Cathérine Legrand, Allan Price, Patrick Rodrigus, J. Belderbos, Joachim G.J.V. Aerts and A. Chemaissani and has published in prestigious journals such as Annals of Oncology, Thorax and Nutrients.

In The Last Decade

Nico van Walree

10 papers receiving 314 citations

Peers

Countries citing papers authored by Nico van Walree

Since Specialization

Citations

This map shows the geographic impact of Nico van Walree's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nico van Walree with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nico van Walree more than expected).

Fields of papers citing papers by Nico van Walree

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nico van Walree. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nico van Walree. The network helps show where Nico van Walree may publish in the future.

Co-authorship network of co-authors of Nico van Walree

This figure shows the co-authorship network connecting the top 25 collaborators of Nico van Walree. A scholar is included among the top collaborators of Nico van Walree based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nico van Walree. Nico van Walree is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

#	Work	Indexed citations
1	High Protein Oral Nutritional Supplements Enable the Majority of Cancer Patients to Meet Protein Intake Recommendations during Systemic Anti-Cancer Treatment: A Randomised Controlled Parallel-Group Study 2023 ·Nutrients ·Anne‐Marie C. Dingemans, Nico van Walree, Franz M.N.H. Schramel, (unknown), (unknown), Willem Lybaert, M. Veldhorst, (unknown), Stein Kaasa	9
2	Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19): an investigator-initiated, randomised, open-label, phase 2 trial 2021 ·The Lancet Respiratory Medicine ·Cornedine J. de Gooijer, Vincent van der Noort, Jos A. Stigt, Paul Baas, Bonne Biesma, Robin Cornelissen, Nico van Walree, (unknown), (unknown), Harry J.M. Groen, A.J. Staal-van den Brekel, Wieneke A. Buikhuisen, (unknown), Floris Dammeijer, Harm van Tinteren, Ferry Lalezari, Joachim G.J.V. Aerts, Jacobus A. Burgers	28
3	Genetic polymorphism in ATIC is associated with effectiveness and toxicity of pemetrexed in non-small-cell lung cancer 2021 ·Thorax ·Sabine Visser, Stijn L.W. Koolen, (unknown), Nico van Walree, Cor van der Leest, Robin Cornelissen, Ron van Schaik, Ron H.J. Mathijssen, Joachim G.J.V. Aerts, Bruno H. Stricker	6
4	LBA50 A randomized phase III study comparing cisplatin-pemetrexed (cis-pem) with carboplatin (C)-paclitaxel (P)-bevacizumab (B) in chemotherapy naïve patients (pts) with advanced KRAS mutated non-small cell lung cancer (NSCLC): NVALT22 2021 ·Annals of Oncology ·Anne‐Marie C. Dingemans, Scott Ernst, Wouter W. Mellema, Sjaak A. Burgers, (unknown), Lizza Hendriks, T. Jeroen N. Hiltermann, Nico van Walree, (unknown), (unknown), Bonne Biesma, (unknown), Egbert F. Smit, (unknown)	4
5	The association of depressive symptoms, personality traits, and sociodemographic factors with health-related quality of life and quality of life in patients with advanced-stage lung cancer: an observational multi-center cohort study 2020 ·BMC Cancer ·(unknown), Sabine Visser, Joachim G.J.V. Aerts, Paul Lodder, Nico van Walree, Huub Belderbos, Brenda L. Den Oudsten	19
6	Switch Maintenance Gemcitabine after First Line Chemotherapy in Patients with Malignant Mesothelioma: A Randomized Open Label Phase II Trial (NVALT19) 2020 ·SSRN Electronic Journal ·Cornedine J. de Gooijer, Vincent van der Noort, Jos A. Stigt, Paul Baas, Bonne Biesma, Robin Cornelissen, Nico van Walree, (unknown), (unknown), Harry J.M. Groen, A.J. Staal-van den Brekel, Wieneke A. Buikhuisen, (unknown), Floris Dammeijer, Harm van Tinteren, Ferry Lalezari, Joachim G.J.V. Aerts, Jacobus A. Burgers	1
7	Frequency of low-grade adverse events and quality of life during chemotherapy determine patients’ judgement about treatment in advanced-stage thoracic cancer 2019 ·Supportive Care in Cancer ·(unknown), Sabine Visser, Brenda L. Den Oudsten, Paul Lodder, Nico van Walree, Huub Belderbos, Joachim G.J.V. Aerts	8
8	SUVmax during 18FDG-PET scanning in small cell lung cancer: Similar information as in non-small cell lung cancer? 2011 ·Lung Cancer ·Cor van der Leest, Egbert F. Smit, Jara M. Baas, (unknown), Nico van Walree, Henk C. Hoogsteden, Joachim G.J.V. Aerts	19
9	Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973) 2006 ·European Journal of Cancer ·J. Belderbos, (unknown), Nico van Zandwijk, Huub Belderbos, Patrick Rodrigus, (unknown), Allan Price, Nico van Walree, Cathérine Legrand, (unknown), Harry Bartelink, Giuseppe Giaccone, (unknown)	141
10	Single-agent gemcitabine versus cisplatin-etoposide: Early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer 1997 ·Annals of Oncology ·C. Manegold, Bengt Bergman, A. Chemaissani, W. Dornoff, P. Drings, (unknown), Kari Liippo, K. Mattson, Joachim von Pawel, Serafino Ricci, Christer Sederholm, R. Stahel, Gunnar Wagenius, Nico van Walree, (unknown)	91

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact